Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs?
An increasing number of studies, both experimental and epidemiologic, have provided evidence that filtering glaucoma surgery may be less effective than initially described. Of a number of risk factors for failure, duration and number of antiglaucoma drugs prior to surgery seem to play a critical role and highly accumulated antiglaucoma topical treatments significantly reduce success rates. Histopathological studies have confirmed that topically applied drugs may exert toxic effects to the corneoconjunctival surface, and induce chronic infraclinical inflammation, as shown by the presence of immune and inflammatory infiltrates in multitreated eyes. The origin of topical inflammation has not yet been clearly determined, but a common component of ophthalmic drugs, the benzalkonium chloride used as preservative in almost all antiglaucoma preparations, has shown strong evidence of toxicity. A number of questions remain to be investigated, but suppression of preservatives from chronically applied drugs should be a critical issue in the near future.
Baudouin
C
C
Department of Ophthalmology, Ambroise Paré Hospital, University of Paris-Ouest, Boulogne, France.
D000818:Animals; D001548:Benzalkonium Compounds / Q000009:adverse effects; D003228:Conjunctiva / Q000187:drug effects / Q000473:pathology / Q000601:surgery*; D005123:Eye / Q000187:drug effects* / Q000473:pathology; D005901:Glaucoma / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D009883:Ophthalmic Solutions / Q000009:adverse effects*; D010277:Parasympathomimetics / Q000009:adverse effects; D010862:Pilocarpine / Q000009:adverse effects; D011310:Preservatives, Pharmaceutical / Q000009:adverse effects*; D012307:Risk Factors; D014130:Trabeculectomy; D017211:Treatment Failure
D001548:Benzalkonium Compounds; D009883:Ophthalmic Solutions; D010277:Parasympathomimetics; D011310:Preservatives, Pharmaceutical; D010862:Pilocarpine